While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...

The 30-day risks of hospitalization were 17.5%, 15.9%, and 14.4% for COVID, influenza, and RSV, respectively, during the 2022 ...

COVID-19 was associated with more severe disease outcomes than influenza or respiratory syncytial virus (RSV) during ...

Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...

Wales is past the peak of its flu season according to public health bosses. Cases of flu have caused chaos in Wales' ...

The Cyprus pulmonology society on Thursday urged Health Minister Michael Damianos to approve a respiratory syncytial virus (RSV) vaccine for use Cyprus. The society also seeks its inclusion into the ...

RSV is usually contagious for three to eight days. A patient also may be contagious a day or two before experiencing symptoms ...

Sanofi’s jump in earnings comes with an increased emphasis on R&D and vaccines, plus an eye cast toward M&A to shore up its pipeline.

The Health Protection Surveillance Centre (HPSC) has reported a further reduction in cases of flu, the Respiratory Syncytial ...

UPMC saw an increase in RSV cases in its health system, including in Lancaster County, a spokesperson said Jan. 7, especially ...

Tis the season—for the flu, COVID, stomach bugs, and other nasty viruses that can knock us down for several days, causing ...

At the start of every week, our team talks with local experts to unpack a wide range of nationwide health, safety, and ...